Expansion into Canadian Market Strengthens Global Footprint
Respiratory imaging pioneer 4DMedical (ASX: 4DX) has just scored a major regulatory win, securing Health Canada approval for its CT Lung Ventilation Analysis Software (CT LVAS™). This milestone expands 4DMedical’s presence in the high-value Canadian healthcare market, adding to its existing approvals for Lung Density Analysis (LDA), Lung Texture Analysis (LTA), and Lung Nodules.
Why This Matters
- Canada is a lucrative market, spending 63% more on healthcare than Australia.
- 40+ million population, US$2.1T GDP, and 560 CT scanners nationwide make it a prime target for expansion.
- Respiratory imaging accounts for 12.7% of 6.4M annual CT scans, presenting a massive growth opportunity.
CT LVAS™: A Game-Changer for Lung Imaging
CT LVAS™ uses standard CT scans to provide insights into lung ventilation without requiring additional imaging or contrast agents. This makes it a cost-effective and efficient tool for diagnosing and monitoring lung diseases like COPD and other respiratory conditions.
CEO Andreas Fouras: “Perfect Timing for Expansion”
4DMedical’s MD & CEO Andreas Fouras emphasized the strategic advantage of Canada’s proximity to the U.S., making it a natural fit for the company’s North American sales strategy.
“With most Canadians living close to the U.S. border, our sales team is well-positioned to drive adoption. We’ve cracked the code on scaling our technology, with a 24% increase in sites, a 10% rise in scans per site, and a 12% jump in average fees per scan in the last half-year. Now is the perfect time to bring CT LVAS™ to Canada.”
Looking Ahead: Next Stop, CT:VQ™ Approval
With CT LVAS™ now approved, 4DMedical is paving the way for its next breakthrough product—CT:VQ™. This technology integrates ventilation and perfusion imaging for a more comprehensive lung function assessment, further strengthening the company’s North American expansion strategy.
